AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB

Wednesday, November 14, 2007 General News
Email Print This Page Comment
Font : A-A+

TUSTIN, Calif., Nov. 13 AMDL, Inc. (Amex: ADL)reported today that it has filed a Form 12b-25 with the Securities andExchange Commission indicating that its Form 10-QSB for the six months endedSeptember 30, 2007 would not be filed by November 14, 2007. However, AMDLexpects to file the required report by November 19, 2007, in the time allottedby the Rules. Gary L. Dreher, President, stated: "Accounting for ouroperations in China is challenging and we need the additional time to properlyprepare the Form 10-QSB."

About AMDL

AMDL, Inc., headquartered in Tustin, California, with operations inShenzhen, Jaingxi and Jilin China through its wholly owned subsidiary JadePharmaceutical Inc., is an international biopharma company. AMDL togetherwith Jade engages in the development, manufacture and marketing of proprietarypharmaceutical and testing products. More information about AMDL and itsproducts can be obtained at http://www.amdl.com.

Forward-Looking Statements

Statements in this press release may constitute forward-looking statementsand are subject to numerous risks and uncertainties, including the failure tocomplete successfully the development of new or enhanced products, theCompany's future capital needs, the lack of market demand for any new orenhanced products the Company may develop, any actions by the Company'spartners that may be adverse to the Company, the success of competitiveproducts, other economic factors affecting the Company and its markets, andother risks detailed from time to time in the Company's filings with theSecurities and Exchange Commission. The actual results may differ materiallyfrom those contained in this press release. The Company disclaims anyobligation to update any statements in this press release.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460

SOURCE AMDL, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook